Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

Patent granted, share price up: Archer Materials reaches significant milestone

  • In News
  • September 23, 2021
  • Samantha Freidin
Patent granted, share price up: Archer Materials reaches significant milestone

Shareholders will be pleased to read that Archer Materials (ASX: AXE) has been granted a US patent for their 12CQ quantum computer chip. 

The highly anticipated announcement comes after a media fumble last month that saw a popular Australian financial news masthead report several inaccuracies, prompting the Company to respond with a curt market release. 

The granting of the patent is Archer’s most significant early-stage commercialisation milestone to date, protecting their IP and opening up further opportunities for partnerships in the US. The region is known for its innovative approach to semiconductor and computing technology. 

In an effort to stake their claim as global technology leaders, the US has recently entered into a partnership with Australia and the UK to form AUKUS to focus on quantum technologies in security. The US has also passed key legislation regarding quantum computing through the National Quantum Initiatives Act and the Innovation and Competition Act, a US$250 billion investment in science and technology. The Innovation and Competition Act could inject billions into the US domestic semiconductor industry. 

Archer now holds patents for the 12CQ chip in four jurisdictions including Japan, South Korea, China and now, the US. Patents are pending in Australia, Europe and Hong Kong. 

Dr. Mohammad Choucair welcomed the news, saying: “Archer’s 12CQ quantum computing chip IP is now protected in the US. The Company has achieved a major early stage commercialisation milestone with the granting of the US patent.”

“The 12CQ chip Archer is developing is an entirely new technology in the semiconductor industry that could potentially allow for the future operation of practical quantum computing devices. 

“Most of the investments, R&D, innovation and commercialisation in quantum computing takes place in, or originates from, the US. At the core of this thriving innovation ecosystem are patents and the accompanying IP rights. 

“Archer is one of the few companies with a patent portfolio protecting quantum computing chip technology and one with a unique global competitive advantage.

“We continue to work through the patent application processes related to the 12CQ chip in Europe, Australia and Hong Kong.”

Forums and discussion platforms were abuzz yesterday with keen interest in the stock which was reflected over the past week with AXE shares rallying from $1.64 to last close at $2.11.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.